ClinicalTrials.gg
CompletedNCT03961529Updated Nov 19, 2021Results posted

Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis

A Phase 3 interventional study of 0.3% OPA-15406 ointment and 1% OPA-15406 ointment in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.

Enrollment
2nd of 16
366 · median 177
Started
2019
with 2 others
Phase 3
10 of 16
2 open now
Registered
9th of 16
by date
Lead sponsor
9 of 16
Otsuka Pharmaceutical Co., Ltd.

Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 9th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difamilast

difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing difamilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

To demonstrate the safety of 1% OPA-15406 ointment in adult patients with AD and of 0.3% and 1% OPA-15406 ointments in pediatric patients with AD administered twice daily for 52 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: At least 2 years (at time of obtaining )
  • Diagnosis of AD based on the Japanese Dermatological Association's criteria
  • Atopic dermatitis affecting ≥5% of body surface area (BSA, excluding scalp) at the screening and baseline examinations

Exclusion criteria

Exclusion Criteria:

  • Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    0.3% OPA-15406 ointment

    Twice daily

    Drug: 0.3% OPA-15406 ointment

  • Experimental
    1% OPA-15406 ointment

    Twice daily

    Drug: 1% OPA-15406 ointment

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs)

    The number of subjects were calculated regarding adverse events occurring after IMP administration (=TEAEs).

    Time frame: Treatment period (52 weeks)

Secondary outcomes

  1. Responder Rate of Investigator's Global Assessment (IGA)

    The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 52. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.

    Time frame: Week 52

  2. Responder Rate of Eczema Area and Severity Index 75 (EASI 75)

    The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD. The investigator or sub investigator scored the severity (0-3 points) and affected body surface area (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). EASI 75 is defined as the rate of subjects whose EASI score has improved at least 75% from baseline.

    Time frame: Week 52

07

Results

Posted Nov 19, 2021

Participant flow

Participant flow — Overall Study
MilestoneAdult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 Ointment
Started16614456
Completed12412751
Not completed42175
Withdrew: Adverse event1352
Withdrew: Withdrawal by subject1721
Withdrew: Withdrawal by parent/guardian070
Withdrew: Physician decision211
Withdrew: Lost to follow-up210
Withdrew: Lack of efficacy201
Withdrew: Other610

Outcome measures

PrimaryNumber of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs)

The number of subjects were calculated regarding adverse events occurring after IMP administration (=TEAEs).

Time frame:
Treatment period (52 weeks)
Reported as:
Count of participants · Participants
Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs)
ParticipantsAdult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 Ointment
Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs)12013147
SecondaryResponder Rate of Investigator's Global Assessment (IGA)

The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 52. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Responder Rate of Investigator's Global Assessment (IGA)
percentage of participantsAdult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 Ointment
Responder Rate of Investigator's Global Assessment (IGA)34.94 (27.71 to 42.71)52.78 (44.29 to 61.15)51.79 (38.03 to 65.34)
SecondaryResponder Rate of Eczema Area and Severity Index 75 (EASI 75)

The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD. The investigator or sub investigator scored the severity (0-3 points) and affected body surface area (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). EASI 75 is defined as the rate of subjects whose EASI score has improved at least 75% from baseline.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Responder Rate of Eczema Area and Severity Index 75 (EASI 75)
percentage of participantsAdult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 Ointment
Responder Rate of Eczema Area and Severity Index 75 (EASI 75)55.42 (47.52 to 63.13)77.08 (69.35 to 83.67)64.29 (50.36 to 76.64)

Adverse events

Collected over Treatment period (52 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adult: 1% OPA-15406 Ointment0/166 (0%)2/166 (1.2%)72/166 (43.4%)
Pediatric: 0.3% OPA-15406 Ointment0/144 (0%)1/144 (0.7%)108/144 (75%)
Pediatric: 1% OPA-15406 Ointment0/56 (0%)0/56 (0%)43/56 (76.8%)
Most frequent serious events
Most frequent serious events
EventAdult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 Ointment
Pneumonia bacterialInfections and infestations0/1661/1440/56
Rhegmatogenous retinal detachmentEye disorders1/1660/1440/56
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1660/1440/56
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAdult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 Ointment
NasopharyngitisInfections and infestations24/16647/14417/56
Dermatitis atopicSkin and subcutaneous tissue disorders35/16630/14417/56
ImpetigoInfections and infestations2/16626/1445/56
InfluenzaInfections and infestations5/16621/1444/56
Conjunctivitis allergicEye disorders5/16614/1447/56
GastroenteritisInfections and infestations5/16611/1446/56
UrticariaSkin and subcutaneous tissue disorders8/16614/1443/56
FolliculitisInfections and infestations10/1669/1445/56
PharyngitisInfections and infestations0/1666/1444/56
BronchitisInfections and infestations1/1669/1443/56

Baseline characteristics

Safety set: subjects who have received the investigational medicinal product (IMP) at least once

Age, Continuous
Age, Continuous(years)Adult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 OintmentTotal
Mean33.7 ± 11.37.1 ± 3.58.3 ± 3.57.4 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)Adult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 OintmentTotal
Female656318146
Male1018138220
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Adult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 OintmentTotal
Asian16614456366
Region of Enrollment
Region of Enrollment(Participants)Adult: 1% OPA-15406 OintmentPediatric: 0.3% OPA-15406 OintmentPediatric: 1% OPA-15406 OintmentTotal
Japan16614456366
08

Study locations

1 site
  • Shirao clinic of pediatrics and pediatric allergy
    Hiroshima, Japan
09

References and documents

Publications

  • Saeki H, Imamura T, Yokota D, Tsubouchi H. Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study. Dermatol Ther (Heidelb). 2022 Jul;12(7):1589-1601. doi: 10.1007/s13555-022-00751-9. Epub 2022 Jun 18. PubMed 35716332 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Nov 2020, 17 months.

Results were first posted in Nov 2021, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 17 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2019
First posted
May 23, 2019
StartActual
May 14, 2019
Primary completionActual
Nov 11, 2020
CompletionActual
Nov 11, 2020
Results first posted
Nov 19, 2021
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03961529
Responsible party
Sponsor
First posted
May 23, 2019
Start date
May 14, 2019
Primary completion
Nov 11, 2020
Completion
Nov 11, 2020
Results posted
Nov 19, 2021
Last update
Nov 19, 2021

Study contacts

Osamu Sato
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difamilast

Start the discussion